Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Results of ELOQUENT-2 trial for treatment multiple myeloma

Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.